Commit to

A data driven approach and rigorous scientific process

Our Story

Lung Cancer Proteomics has spent 13 years developing a simple blood test that can detect early stage Non-Small Cell Lung Cancer (NSCLC) with high sensitivity and specificity. Our approach focuses on evaluating protein biomarkers in conjunction with proprietary algorithms and patient demographic information to provide a risk assessment for early stage lung cancer. We chose protein markers as it reflects information on the physiological condition of the tissue as a result of interaction between the genotype and the environment. Over the years, our company have discovered novel markers that may be related to lung cancer or have validated known markers with potential for diagnostic use in lung cancer. These discoveries have led to multiple patents and publications. In 2016, we completed the validation of the Lung Cancer Detection Test 1 (LCDT1). The LCDT1 is a simple blood test that detects Stage 1 lung cancer at ~95% accuracy. The LCDT1 will revolutionize the way lung cancer is detected leading to early intervention and a better quality of life.

Insert Content Template or Symbol
Insert Content Template or Symbol
Insert Video

Lung Cancer Proteomics, LLC
Headquarters
105 Washington Street
Michigan City, IN 46360

Bay Area Laboratory
780 Montague Expressway
Building 7, Suite 703
San Jose, CA 95131

LinkedIn - Lung Cancer Proteomics
Twitter - Lung Cancer Proteomics
Facebook - Lung Cancer Proteomics

© 2019 Lung Cancer Proteomics. All rights reserved.